



# Financial Tear Sheet

## CORPORATE PROFILE

Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.

## PRIMARY IR CONTACT


E-mail: [ir@motifbio.com](mailto:ir@motifbio.com)

## STOCK DETAILS

MTFB (ADS)	
<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	<b>\$7.71</b>
<b>Change (%)</b>	▼ 0.06 (0.77%)
<b>Volume</b>	310
<b>52 Week Low</b>	\$6.94
<b>Market Cap</b>	\$
<b>Rolling EPS</b>	0.00
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	

Data as of November 16, 2018 3:48 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



# RECENT NEWS & UPCOMING EVENTS

October 31, 2018

There are currently no events scheduled.

Motif Bio to participate at upcoming Jefferies London

Healthcare Conference

October 3, 2018

Motif Bio Presents New Iclaprim Data at IDWeek

September 25, 2018

Motif Bio Reports Half-Year 2018 Financial Results and

Operational Progress

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
September 25, 2018	6-K
August 21, 2018	6-K
August 14, 2018	6-K
August 8, 2018	6-K